FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers

Nerviano Medical Sciences (NMS): Green Light From the FDA for the CDC7 Inhibitor

NERVIANO, Italy, February 10 (HSMN NewsFeed) -- Nerviano Medical Sciences (NMS) has secured Food and Drug Administration (FDA) approval to conduct for the first time clinical trials of a novel antitumoral agent. The drug blocks Cdc7, a protein that is responsible for the uncontrolled proliferation of cancer cells. The preclinical data, recently published on the prestigious journal Nature Chemical Biology ( http://www.nature.com/nchembio/journal/v4/n6/full/nchembio.90.html), demonstrate that inhibition of Cdc7 induces tumor cell death and blocks the growth of various types of cancer in experimental animal models.

Full text >>